-
Product Insights
Net Present Value Model: BX-004
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model BX-004 Drug Details BX-004 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BX-004
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry BX-004 Drug Details BX-004 is under development for the treatment of cystic fibrosis and...
-
Product Insights
Cystic Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis – Drugs In Development, 2022, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe...
-
Product Insights
Resistant Pseudomonas aeruginosa Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Resistant Pseudomonas Aeruginosa Infections have an ability to rapidly develop resistance to multiple classes of antibiotics. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers, and headache. Risk factors include age and a weak immune system. The Resistant Pseudomonas Aeruginosa Infections pipeline drugs market research report provides an analysis of the Resistant Pseudomonas aeruginosa Infections drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the...
-
Product Insights
Primary Sclerosing Cholangitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Primary Sclerosing Cholangitis pipeline market research report provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Primary Sclerosing Cholangitis...
-
Product Insights
Atopic Dermatitis (Atopic Eczema) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Atopic Dermatitis is an itchy inflammation of skin. Signs and symptoms of Atopic Dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender. The Atopic Dermatitis - Drugs In Development research report provides a comprehensive overview on the...
-
Thematic Analysis
Microbiome – Targeted Therapeutics in Immunology – Thematic Research
The microbiome is considered the genetic material of all microorganisms existing in and on the human body. Although the primary site of aggregated microbes is in the gastrointestinal (tract, populations of microorganisms are also found on the surface of the skin as well as in the upper and lower respiratory tract. The microbiome-targeting therapeutics in immunology thematic research report will help you in developing and designing your in-licensing and out-licensing strategies, using a detailed overview of current deals and technologies...